PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2016 Aug 19

PMID 27535979

Citations 198

Authors

Mizuki Nishino

Nikhil H Ramaiya

Mark M Awad

Lynette M Sholl

Jennifer A Maattala

Myriam Taibi

Hiroto Hatabu

Patrick A Ott

Philippe F Armand

F Stephen Hodi

Affiliations

Soon will be listed here.

Abstract

Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer patients.

Experimental Design: Among patients with advanced melanoma, lung cancer, or lymphoma treated in trials of nivolumab, we identified those who developed pneumonitis. Chest CT scans were reviewed to assess extent, distribution, and radiographic patterns of pneumonitis.

Results: Among 170 patients treated in 10 different trials of nivolumab, 20 patients (10 melanoma, 6 lymphoma, and 4 lung cancer) developed pneumonitis. Five patients received nivolumab monotherapy, and 15 received combination therapy. The median time from therapy initiation to pneumonitis was 2.6 months. Radiographic pattern was cryptogenic organizing pneumonia (COP) in 13, nonspecific interstitial pneumonia (NSIP) in 3, hypersensitivity pneumonitis (HP) in 2, and acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) in 2 patients. The AIP/ARDS pattern had the highest grade, followed by COP, whereas NSIP and HP had lower grade (median grade: 3, 2, 1, 1, respectively; P = 0.006). The COP pattern was most common in all tumors and treatment regimens. Most patients (17/20; 85%) received corticosteroids, and 3 (15%) also required infliximab. Seven patients restarted nivolumab therapy; 2 of them developed recurrent pneumonitis and were successfully retreated with corticosteroids. One of the patients experienced a pneumonitis flare after completion of corticosteroid taper without nivolumab retreatment.

Conclusions: PD-1 inhibitor-related pneumonitis showed a spectrum of radiographic patterns, reflecting pneumonitis grades. COP was the most common pattern across tumor types and therapeutic regimens. Most patients were successfully treated with corticosteroids. Recurrent pneumonitis and pneumonitis flare were noted in a few patients. Clin Cancer Res; 22(24); 6051-60. ©2016 AACRSee related commentary by Castanon, p. 5956.

Citing Articles

Imaging Findings of Complications of New Anticancer Drugs.

Jang J, Park H, Suh C, Won S, Lee E, Kim N Korean J Radiol. 2025; 26(2):156-168.

PMID: 39898396 PMC: 11794286. DOI: 10.3348/kjr.2024.0195.

Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review.

Podder V, Ranjan T, Margolin K, Maharaj A, Ahluwalia M Cancers (Basel). 2024; 16(23).

PMID: 39682118 PMC: 11640090. DOI: 10.3390/cancers16233929.

Clinical and histopathological features of immune checkpoint inhibitor-induced lung toxicity.

Rolim I, Lopez-Beltran A, Ip J, Nunes B, Coelho R, Pantarotto M Virchows Arch. 2024; .

PMID: 39578288 DOI: 10.1007/s00428-024-03976-5.

Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts.

Fontes E Sousa M, Campainha S, Marques I, Dinis R, Inacio J, Mendes J Clin Drug Investig. 2024; 44(11):801-810.

PMID: 39500817 PMC: 11564330. DOI: 10.1007/s40261-024-01400-z.

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.

Cheema P, Iafolla M, Abdel-Qadir H, Bellini A, Chatur N, Chandok N Curr Oncol. 2024; 31(10):6356-6383.

PMID: 39451777 PMC: 11506662. DOI: 10.3390/curroncol31100473.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Nishino M, Brais L, Brooks N, Hatabu H, Kulke M, Ramaiya N . Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016; 53:163-70. PMC: 4724503. DOI: 10.1016/j.ejca.2015.10.015. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N . Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12. PMC: 4672027. DOI: 10.1200/JCO.2014.58.3708. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

Nishino M, Boswell E, Hatabu H, Ghobrial I, Ramaiya N . Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist. 2015; 20(9):1077-83. PMC: 4571812. DOI: 10.1634/theoncologist.2015-0033. View

Mcdermott D, Drake C, Sznol M, Choueiri T, Powderly J, Smith D . Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015; 33(18):2013-20. PMC: 4517051. DOI: 10.1200/JCO.2014.58.1041. View

Nishino M, Tirumani S, Ramaiya N, Hodi F . Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015; 84(7):1259-68. PMC: 4450141. DOI: 10.1016/j.ejrad.2015.03.017. View

Nishino M, Sholl L, Hodi F, Hatabu H, Ramaiya N . Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015; 373(3):288-90. PMC: 4539956. DOI: 10.1056/NEJMc1505197. View

10.

Robert C, Ribas A, Wolchok J, Hodi F, Hamid O, Kefford R . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948):1109-17. DOI: 10.1016/S0140-6736(14)60958-2. View

11.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

12.

Tirumani S, Ramaiya N, Keraliya A, Bailey N, Ott P, Hodi F . Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015; 3(10):1185-92. PMC: 4596761. DOI: 10.1158/2326-6066.CIR-15-0102. View

13.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

14.

Maroto J, Hudes G, Dutcher J, Logan T, White C, Krygowski M . Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011; 29(13):1750-6. DOI: 10.1200/JCO.2010.29.2235. View

15.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

16.

Motzer R, Rini B, Mcdermott D, Redman B, Kuzel T, Harrison M . Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014; 33(13):1430-7. PMC: 4806782. DOI: 10.1200/JCO.2014.59.0703. View

17.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

18.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

19.

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View

20.

Rizvi N, Mazieres J, Planchard D, Stinchcombe T, Dy G, Antonia S . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16(3):257-65. PMC: 5726228. DOI: 10.1016/S1470-2045(15)70054-9. View